Overview

N-acetylcysteine for Tobacco Smoking

Status:
Unknown status
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy of N-acetylcysteine (NAC) for smoking cessation in a double blind, randomized, placebo-controlled trial. Simultaneously, the study aims to elucidate the role of inflammatory markers and oxidative stress related to nicotine addiction and the use of NAC, an acetylated precursor of cysteine, a naturally occurring amino acid that has antioxidant actions in its own right, in reducing oxidative stress and inflammation in smokers. It will evaluate the use of NAC in smoking cessation, after 4, 8 and 12 weeks of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Universidade Estadual de Londrina
Treatments:
Acetylcysteine
N-monoacetylcystine